Aurora Spine Corporation Announces Co-Marketing Agreement

CARLSBAD, Calif., Feb. 24 12, 2022 (GLOBE NEWSWIRE) — Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB: ASAPF), a manufacturer of innovative spinal implants, announced today that it has entered into an agreement co-marketing agreement with Echolight Medical, a manufacturer of the portable, non-radiation EchoS densitometer used for patient assessment of bone mineral density (BMD) and bone microarchitecture quality independent of BMD.

Aurora develops and manufactures spinal implants based on DEXA technology, and Echolight is dedicated to assessing bone health without the use of ionizing radiation. Both companies have agreed to promote each other’s products under the Aurora DEXA platform to their respective customers and prospects.

This mutual effort allows Aurora to combine Echolight’s bone health assessment capabilities with its proprietary patient-friendly implants based on DEXA technology and enables Echolight to market and promote Echolight’s devices to determine which Aurora’s DEXA technology implants is most suitable for each patient’s normal, osteopenic bone quality. or osteoporosis.

Trent Northcutt, CEO and President of Aurora Spine, said, “Aurora is excited to work with Echolight and deliver comprehensive bone scanning capabilities with Aurora’s patient-friendly DEXA Platform line of spinal implants. This joint effort will provide patients with a one-stop-shop for patient-tailored implants based on fast and accurate real-time bone quality analysis with immediately available reports. We firmly believe that our partnership and shared passion will expand access to healthcare for more people.

Doug Tefft, President of Echolight, said, “We are excited to contribute to Aurora’s innovative DEXA platform. This allows Echolight to provide orthopedic and spinal treatment support in addition to bone health assessment for osteoporosis. Echolight devices are widely used in Europe and have recently been launched in the United States. Echolight expects significant clinical impact by combining its radiation-free, wearable devices in the United States with the only patented, FDA-cleared compatible bone-grade fusion devices,” said Doug Tefft, President of Echolight USA. “It is a privilege to partner with the Aurora team in the field of spinal and orthopedic fixation.”

Laszlo Garamszegi, Aurora Spine’s Chief Technology Officer, added, “Both companies received positive feedback from attendees at the 2022 Orthopedic Research Society meeting in Tampa that Aurora’s DEXA technology and Echolight REMS work well together and complement each other in the diagnosis and treatment of bone quality. patients with spinal diseases requiring fusion surgery. We believe that our mutual efforts with the Echolight team will bring new solutions to market and raise the standard of care for patients.

On echolight

Echolight Medical has developed the first clinically available method for direct non-ionizing measurement of lumbar and femoral bone mineral density (BMD).

The device, EchoS, uses proprietary REMS (Multi-Spectrometry Ultrasound Radiofrequency) technology to scan the lumbar vertebrae and proximal femur. The EchoS quickly generates a medical report including BMD, T-score, and Z-score. In addition, the system automatically assesses the quality of bone microarchitecture, independent of BMD, and provides a five-year probability of a fracture. major osteoporosis.

EchoS offers dramatically increased levels of accuracy, sensitivity to changes in bone mass, and diagnostic reproducibility over DXA systems. This, together with the absence of ionizing radiation, allows for broader and earlier diagnosis of osteoporosis at the point of care. It also allows for more accurate post-diagnostic monitoring. To learn more about the FDA-cleared EchoS, visit:

About Aurora Spine

Aurora Spine is focused on bringing new solutions to the spinal implant market through a series of innovative, minimally invasive and regenerative spinal implant technologies. Additional information is available at or

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements

This press release contains forward-looking information that involves important known and unknown risks and uncertainties, most of which are beyond Aurora Spine’s control, including, without limitation, those listed under “Risk Factors” and ” Caution Regarding Forward-Looking Information Information” in Aurora Spine’s final prospectus (collectively, “Forward-Looking Information”). The forward-looking information in this press release includes information regarding the proposed use and success of the Company’s products in surgical procedures. Aurora Spine cautions investors in Aurora Spine securities about important factors that could cause Aurora Spine’s actual results to differ materially from those projected in the forward-looking statements included in this press release. performance are not historical facts and may be forward-looking and may involve estimates, assumptions and uncertainties that could cause actual results to differ one-sidedly from those expressed in such forward-looking statements here will prove to be accurate and, therefore, , potential investors should not place undue reliance on these forward-looking statements. These statements speak only as of the date of this press release and Aurora Spine undertakes no obligation to update or revise them to reflect new events or circumstances.


Aurora Spine Corporation
Trent Northcutt
President and CEO
(760) 424-2004

Chad Clouse
Financial director
(760) 424-2004

Adam Lowensteiner
Phoenix | new York
Phone: 646-829-9700
[email protected]

Contact Echolight:
Doug Teft
President – ​​Echolight Medical USA
(425) 503-4840
[email protected]